Paracap

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Paracap

Defining Paracap: Identity and Core Function

Property Description
Active Ingredient Paracetamol (Acetaminophen)
Form & Strength Oral Solid (e.g., 500 mg Tablet)
Pharmacological Class Non-opioid Analgesic; Antipyretic
Primary Use Pain relief and fever reduction
Origin Synthetic (Manufactured)

Paracap is a brand of over-the-counter (OTC) medicine that contains the active pharmaceutical ingredient (API) paracetamol, known as acetaminophen in the United States. It is chemically synthetic and is classified pharmacologically as a non-opioid analgesic and antipyretic. This means its primary function is focused on managing mild-to-moderate pain and lowering elevated body temperature.


Composition, Class, and Purpose

Paracap provides symptomatic relief for acute, short-term discomforts such as headaches, muscular aches, and fever associated with the common cold. The active ingredient, paracetamol, has been clinically recognized for decades as a first-line therapy for acute pain and fever. This established efficacy makes Paracap a trusted option for managing everyday aches and reducing a high temperature.

Its classification as an aniline analgesic differentiates it from nonsteroidal anti-inflammatory drugs (NSAIDs). While NSAIDs target inflammation, Paracap's therapeutic action is centered primarily in the central nervous system, making it a targeted agent for fever and pain without major peripheral anti-inflammatory effects. This property makes the medicine suitable for patients who specifically require focused pain and fever management.

Regulatory References

  1. NIH MedlinePlus Drug Information: Acetaminophen

What side effects are possible with Paracap?

Possible Side Effects and Safety Information

The safety profile of Paracap, which contains paracetamol (acetaminophen), is based on official government regulatory documents. Adverse reactions are generally classified as Rare or Very Rare, and the most critical safety issues involve the liver and skin.

Documented Adverse Reactions and Frequencies

Adverse reactions are documented across several System-Organ Classes (SOCs). Frequency classifications are standardized across regulatory bodies:

Classification Examples of Reactions Affected System-Organ Class
Rare (1/1,000 to 1/10,000) Generally mild effects Various
Very Rare (<1/10,000) Thrombocytopenia, Anaphylaxis, Severe Cutaneous Adverse Reactions (SCARs), Severe Hepatic Dysfunction Blood and Lymphatic System, Immune System, Skin, Hepatobiliary
Not Known (Cannot be estimated) Agranulocytosis, Leucopenia, Pancytopenia, Neutropenia, High Anion Gap Metabolic Acidosis (HAGMA) Blood and Lymphatic System, Metabolism and Nutrition

Serious Safety Considerations

Regulatory agencies highlight the potential for Severe Hepatic Failure, which can be fatal, and Severe Cutaneous Adverse Reactions (SCARs), including Stevens-Johnson syndrome (SJS) and Toxic Epidermal Necrolysis (TEN). These are documented as very rare but serious adverse events.

Safety Constraints and Special Populations

Official labeling includes explicit safety restrictions and notes for specific populations:

  • Contraindication: Paracap is strictly contraindicated if there is a known hypersensitivity to the active substance.
  • Concomitant Use: There is an absolute restriction against using this medicine with any other product containing paracetamol, due to the high risk of severe, potentially fatal liver damage.
  • Vulnerable Populations: Caution is required for individuals with existing impaired kidney or liver function, chronic alcohol users, and those with glutathione depleted states (e.g., severe malnutrition or sepsis).

Overdose and Emergency Response

An overdose of Paracap (Paracetamol/Acetaminophen) is classified by regulatory authorities as a severe medical emergency. The earliest documented manifestations, typically appearing within the first 24 hours, may include non-specific symptoms such as nausea, vomiting, pallor, abdominal pain, and diaphoresis (sweating). Critically, a significant overdose may initially be asymptomatic, meaning an individual may feel well despite the progression of internal toxicity.

The primary severe consequence documented in official labeling is fatal or non-fatal hepatic necrosis, often leading to acute liver failure. Other serious outcomes can include metabolic acidosis, coagulopathy, and acute renal failure.

Due to the time-critical risk of delayed, severe liver damage, official regulatory guidance mandates that immediate medical attention must be sought right away following any suspected ingestion, even if the patient feels well and has no current symptoms.

The specific antidote available is N-acetylcysteine (NAC), whose effectiveness is greatest when administered within the first eight hours of ingestion. Regulatory management procedures require measuring the plasma paracetamol concentration at four hours or later post-ingestion. Furthermore, individuals with pre-existing liver disease, chronic alcoholism, or severe malnutrition are documented to be at an increased risk for severe hepatotoxicity following an overdose.

Therapeutic Uses of Paracap

What Paracap Treats: Main Uses and Benefits

Paracap is commonly used across therapeutic domains to offer symptomatic relief, primarily targeting symptoms related to physical discomfort and systemic imbalance. The medication is generally used to relieve mild to moderate pain and to reduce fever, consistent with its function as a supportive agent in acute symptomatic contexts.

It is relevant for conditions characterized by periods of heightened symptoms and is commonly applied in scenarios where additional management of discomfort is required. This includes addressing pain from headache, toothache, muscular aches, backache, and dysmenorrhea, as well as managing fever and systemic aches associated with colds and flu.

“The use of this medication may assist with easing the overall symptom burden and supports patients by helping to relieve distress during symptomatic phases.”

When applied in addressing these symptoms, it contributes to easing the overall symptom load during periods of temporary physiological imbalance.


Fact: Symptomatic Support

Fact: Symptomatic Support

The medication is applicable in clinical settings that involve acute or unstable symptom patterns, helping to relieve symptoms that interfere with daily functioning and supports patients during symptomatic phases.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Contraindicated Populations

Use of Paracap is contraindicated (absolutely must not be used) in specific patient groups, according to official regulatory labeling. These include individuals with known hypersensitivity to the active substance (paracetamol/acetaminophen) or to any excipient in the product. Additionally, the medicine is contraindicated in patients diagnosed with severe hepatic impairment or severe active liver disease.


Age-Group and Condition-Specific Eligibility

Paracap is generally approved for adults and adolescents above the specific age or weight thresholds for a given product formulation. Adult-strength formulations are not recommended for young children. For older adults (geriatric patients), regulatory documents typically note no overall differences in safety or effectiveness compared to younger adults.

Use requires caution or is subject to conditional use in patients with pre-existing conditions such as severe renal impairment, mild to moderate hepatic impairment, chronic alcoholism, chronic malnutrition, or severe hypovolemia. These restrictions relate to patient-specific conditions, not the general safety profile.


Pregnancy and Lactation Status

Paracap may be used during pregnancy if clinically needed, but official guidance strongly recommends utilizing the lowest effective dose for the shortest possible duration. Use during lactation (breastfeeding) is generally considered acceptable, as only minimal amounts are excreted into breast milk.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documentation structures Paracap (Paracetamol) interactions across several categories, outlining specific restrictions and required considerations when co-administered with other substances.


Documented Interaction Patterns

Category Interacting Entities & Official Outcome
Absorption Modifiers Metoclopramide and Domperidone officially accelerate Paracap's absorption rate. Cholestyramine reduces absorption and requires administration separation.
Clearance Modifiers Probenecid reduces Paracap clearance by approximately 50%, inhibiting glucuronidation. Rifampicine and certain anticonvulsants (e.g., Phenytoin) are documented as enzyme inducers that increase the risk of hepatotoxicity.
Pharmacodynamic Effects Prolonged regular use with Warfarin is associated with an enhanced anticoagulant effect, increasing the risk of bleeding. Concurrent use with Flucloxacillin is officially linked to an increased risk of high anion gap metabolic acidosis (HAGMA).

Restrictions and Warnings

Co-administration with other paracetamol-containing products is formally restricted to avoid the risk of serious liver damage from overdose. An increased risk of hepatotoxicity is officially documented for individuals who consume three or more alcoholic drinks per day while using the medicine. Cholestyramine must not be administered within one hour of Paracap if the maximum analgesic effect is required.

Interaction classifications may vary by region, but regulatory bodies consistently emphasize these specific pharmacokinetic and pharmacodynamic patterns for patient safety information.

Mechanism of Action

Functional Mechanism of Paracetamol

The drug's action is concentrated within the Central Nervous System (CNS) through multiple, coordinated pathways. In the brain’s hypothalamus, the active component selectively acts on Cyclooxygenase (COX) enzymes to reduce the local synthesis of Prostaglandin E2 ( PGE2). This molecular change resets the body's elevated thermoregulatory set point, facilitating the physiological process of heat dissipation.

Concurrently, its metabolite, AM404, modulates the Endocannabinoid System (eCB) and TRPV1 channels in the spinal cord and supra-spinal centers. Activation of the CB1 receptor pathway strengthens descending inhibitory pathways, resulting in an elevated nociceptive threshold in the CNS. The mechanism’s activity is functionally limited by hydroperoxide tone; its inhibition of COX is ineffective in the highly oxidative environment of peripheral inflammation, meaning it does not significantly modulate peripheral inflammatory cascades.

Dosage and Administration Information

Official Administration Guidelines

Paracap (paracetamol/acetaminophen) is administered via the primary oral route, encompassing forms such as tablets, capsules, and liquids. In professional healthcare settings, administration may also occur through intravenous (IV) infusion or rectal suppository forms.

The standard adult single dose ranges from 500 mg to 1000 mg (1 g), taken on an as-needed basis. The official dosing schedule mandates a minimum interval of four hours between successive administrations. The most critical constraint is the maximum total daily dose, which must not exceed 4000 mg (4 g) from all sources in a 24-hour period for adults and adolescents ge 12 years.

Specific administration rules include taking the medicine with or without food. Liquid forms require a calibrated device for accurate volume measurement, and IV infusions must be administered slowly over a 15 -minute period. For pediatric use, dosing is strictly determined by body weight (typically 10 mg/kg to 15 mg/kg per dose), not age.

Official labeling requires dose modification for certain patient populations: in cases of severe renal impairment, the dosing interval is prolonged to six or eight hours to prevent accumulation. If a dose is missed, regulatory instructions advise taking the next scheduled dose as needed, provided the minimum four-hour interval has passed, and to never administer a double dose.

Recent Clinical Evidence

Paracap: Recent Clinical Evidence

Clinical research has explored the efficacy and safety profile of Paracap (acetaminophen/paracetamol) across various conditions, particularly focusing on its role in pain and fever management.

Efficacy and Study Outcomes

Studies have assessed the compound's effect primarily in acute and chronic pain settings. High-quality systematic reviews indicate that Paracap provides pain relief for some acute conditions, such as post-operative pain and certain types of headaches. For these acute uses, randomized controlled trials (RCTs) have compared Paracap to placebo.

However, evidence regarding its efficacy in some chronic pain conditions is more limited or inconsistent. Recent meta-analyses evaluating its effect on low back pain and osteoarthritis (OA) of the hip or knee suggest that the short-term benefit, when compared to placebo, may be minimal or not clinically important for many individuals with these specific conditions. Due to this evolving evidence base, clinical practice guidelines continue to be updated to reflect the most current findings.

Safety and Tolerability Insights

Paracap is generally considered well-tolerated at recommended therapeutic doses. Researchers assessed the safety profile across various adult populations, with the most frequently reported adverse events being mild and transient, such as gastrointestinal distress. A key finding from systematic reviews is the risk of transient elevation of liver enzyme levels in patients taking Paracap compared to placebo, particularly with repeated administration, though the clinical significance of this change remains uncertain.

Recent pharmacological studies have also focused on the mechanism by which Paracap is metabolized outside of the liver, leading to a deeper understanding of its complex effects on the body. Ongoing research aims to clarify its exact molecular action and long-term risk profile, especially when used for extended periods.

Frequently Asked Questions (FAQ)

Common questions about Paracap (FAQ)

Q: How fast does Paracap start working after you take it?

A: Official clinical data indicates that when Paracap is taken orally, pain relief typically begins within 30 to 60 minutes. This is when the active ingredient is absorbed into the bloodstream. Individual absorption times can vary slightly.

Q: How long does one dose of Paracap usually last in your system?

A: According to official dosing guidelines, the pain and fever-reducing effects of a single dose generally last for 4 to 6 hours. This duration aligns with the minimum required time interval before another dose is usually recommended.

Q: What's the difference between Paracap and regular over-the-counter pain pills?

A: Paracap's active ingredient, acetaminophen, is classified as an analgesic (pain reliever) and antipyretic (fever reducer). Unlike non-steroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen, official information indicates that Paracap has minimal anti-inflammatory activity. The mechanism of action, which primarily works centrally, means it is generally considered well-tolerated by the stomach and is associated with a lower risk of gastrointestinal bleeding compared to NSAIDs.

Q: Can Paracap make you feel tired or sleepy during the day?

A: Official labeling for single-ingredient acetaminophen, the active component of Paracap, does not typically list drowsiness (somnolence) as a common or frequent side effect. Information regarding combination products containing acetaminophen may list drowsiness as a side effect due to the presence of other active ingredients.

Q: Is it safe to take Paracap if I have stomach issues like ulcers?

A: The active ingredient's primary action is centralized in the nervous system, and it is widely regarded as a pain reliever that is well-tolerated by the stomach. Official product information indicates it is associated with a lower risk of gastrointestinal irritation compared to certain other pain relievers. Patients with severe pre-existing stomach conditions should discuss medication use with their healthcare provider.

Q: What happens if I miss a dose of Paracap?

A: Regulatory instructions advise that if a dose is missed, you should take your next scheduled dose as needed, provided the minimum required time between doses has passed. Official instructions advise against administering a double dose to compensate for a missed one, as this practice greatly increases the risk of overdose and associated liver damage.

Q: Do people take Paracap for nerve pain or muscle spasms?

A: Paracap is officially indicated for the temporary relief of minor aches and pains, which includes muscular aches and backache. However, regulatory labels do not specifically list it as a primary treatment for neuropathic pain (nerve pain) or muscle spasms.

Q: Can Paracap cause any changes in mood or make anxiety worse?

A: While the active ingredient is typically well-tolerated, some post-marketing data reported to regulatory agencies has noted anxiety and insomnia (difficulty sleeping) in rare instances. Any patient experiencing unusual mood changes should report this to their healthcare provider.

Q: How is Paracap different from Tylenol (acetaminophen)?

A: Paracap is a brand name for a medicine containing the active ingredient paracetamol, which is known as acetaminophen in the United States. Tylenol is another brand name for products containing the same active ingredient. Therefore, the core active pharmaceutical ingredient (API) is the same.

Q: Does Paracap show up on standard drug tests?

A: The active ingredient, acetaminophen, is generally not screened for in routine drug-abuse screening panels. However, it can be measured by a specific acetaminophen level blood test, which is typically performed by hospitals to check for potential overdose or toxicity.

Q: Is Paracap known to affect blood pressure?

A: Official labeling for single-ingredient Paracap does not commonly list changes in blood pressure as a side effect. Patients with high blood pressure should be aware that combination products may contain ingredients that can affect blood pressure, requiring consultation with a healthcare professional.

Q: Why does Paracap sometimes cause mild nausea?

A: While generally rare when the medicine is taken as directed, nausea and vomiting are documented side effects. Official information notes that these are the most frequently reported symptoms in cases of overdose or can be listed as mild side effects for some formulations.

Q: Can Paracap interact with herbal supplements like St. John's Wort?

A: Specific interactions with many herbal supplements, including St. John’s Wort, are not explicitly listed as major in all regulatory labels. It is standard guidance to inform a healthcare provider about all herbal and dietary supplements being taken.

Q: Is Paracap appropriate for teens who have pain from sports injuries?

A: Yes, Paracap is approved for use in adolescents and children over 12 years of age (or specific age/weight thresholds) for the temporary relief of minor aches and pains. This includes the kind of muscular aches and minor injuries commonly associated with sports.

Q: Does Paracap have any impact on liver or kidney function over time?

A: Official safety information notes that even at correct doses, chronic use may lead to transient elevations of liver enzymes. Long-term use or taking more than recommended is associated with a risk of severe, potentially fatal, liver damage. Caution is required for patients with pre-existing kidney or liver impairment.

Q: Is it normal to feel a bit restless after taking Paracap?

A: Restlessness or excitement is not commonly listed as a side effect for single-ingredient Paracap in official product information. However, this symptom has been reported, especially in children or when the medicine is combined with stimulating ingredients. If this symptom is experienced, patients should inform their healthcare provider.

Q: Can taking Paracap affect sleep patterns?

A: Post-marketing data reported to regulatory agencies has noted that insomnia (the inability to sleep) can be a side effect of the active ingredient. Additionally, any Paracap product that contains caffeine or other stimulants will carry warnings about potential sleeplessness.

Q: How does the body break down and get rid of Paracap?

A: The active ingredient, acetaminophen, is primarily metabolized (broken down) in the liver. It is chemically changed into substances called conjugates, which are non-toxic, and then these are cleared from the body, mostly through urinary excretion.

Q: Can Paracap cause a skin rash or itching?

A: Yes, regulatory agencies have issued safety warnings that acetaminophen can cause skin reactions, including skin reddening, rash, and itching. In very rare instances, it is associated with severe cutaneous adverse reactions (SCARs), such as Stevens-Johnson Syndrome. These severe skin reactions are very rare, but patients experiencing them should seek immediate medical assistance.

Q: Is there a generic version of Paracap available?

A: Yes, Paracap is a brand name. The active pharmaceutical ingredient, acetaminophen (paracetamol), is available generically from numerous manufacturers, often at a lower cost than the branded version.

Q: Does Paracap have a 'rebound effect' if you stop taking it suddenly?

A: According to official information regarding pain relief medications, the use of acetaminophen in excess of recommended doses for more than 15 days a month may contribute to medication-overuse headaches (sometimes called 'rebound headaches').

Q: Can Paracap be used for managing headaches or migraines?

A: Official regulatory labels indicate that Paracap is indicated for the temporary relief of minor aches and pains, which includes headache. It may be part of a regimen to manage headaches.

Q: Is Paracap safe for people who have asthma or breathing problems?

A: While generally safe for a single dose, official warnings suggest that individuals with a known history of severe asthma or respiratory problems, particularly if related to previous analgesic use, should be cautious. Patients with a history of asthma should discuss the use of this medication with a healthcare professional.

Q: Can Paracap cause dry mouth or changes in taste?

A: Official post-marketing surveillance data has reported dry mouth as a possible side effect of the active ingredient. However, this is typically not listed as a common reaction for single-ingredient products.

Q: Can Paracap interact with common cold or flu medicines?

A: Official regulatory warnings emphasize that co-administration is strictly restricted with any other product containing acetaminophen (paracetamol). This is a critical safety point because many common cold, flu, and allergy medicines contain this ingredient, and taking both greatly increases the severe risk of liver damage from accidental overdose.

Q: Can taking Paracap cause temporary blurred vision?

A: Blurred vision is not a commonly listed side effect for single-ingredient Paracap in official product information. Nevertheless, it has been reported as a rare side effect, sometimes in the context of combination products.

How should Paracap be stored and disposed of?

How to Store and Dispose of Paracap?

Regulatory agencies mandate specific conditions for the storage and disposal of Paracap (Acetaminophen/Paracetamol) to ensure stability and public safety.


Storage Requirements

Paracap must be stored at room temperature, typically below 25 C to 30 C, and protected from excessive moisture and humidity. It is required to be kept in its original packaging and containers must be tightly closed. A fundamental requirement is to keep the medicine out of the sight and reach of children to prevent accidental ingestion.

Disposal Instructions

Unused or expired Paracap should not be disposed of in wastewater (e.g., flushed down the toilet). The preferred method is to use an official drug take-back program. If a take-back option is unavailable, the medicine can be mixed with an undesirable substance (such as dirt) and sealed in a container before being discarded in the household trash, in accordance with local environmental regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Paracap found in:

A-Z Index: